Clinical Focus

  • Neurological Surgery
  • Complex Spine Disorders
  • Minimally Invasive Spine Surgery
  • Brain TumorSurgery
  • Stereotactic Radiosurgery
  • Pediatric Neurological Surgery

Academic Appointments

Administrative Appointments

  • Board of Directors, Chairman & CEO, Accuray, Inc. (manufacturer of the CyberKnife) (1997 - 1999)
  • Board of Directors, California Association of Neurological Surgeons (1996 - 1999)
  • Board of Directors, Chairman (2009-2010), Dalai Lama Foundation (2007 - Present)
  • International Board of Advisors, Council for a Parliament of the World's Religions (2009 - Present)
  • Advisory Board, Heroic Imagination Project (2009 - Present)
  • Board of Directors Vice-Chairman, Friends of New Orleans (2008 - Present)
  • Board of Governors, Tulane University School of Medicine (2007 - Present)
  • Advisory Board, The Fogarty Institute of Innovation (2007 - Present)
  • Board of Directors, The Brain and Creativity Institute at USC (2008 - 2011)
  • Founder & Director, The Center for Compassion and Altruism Research and Education at Stanford (2008 - Present)
  • Director, The Neuroscience Institute at El Camino Hospital (2008 - Present)
  • Advisory Board, Social Chocolate SuperBetter (2011 - Present)
  • Board of Directors, Association for Medical Ethics (2012 - Present)
  • Advisory Board, Greater Good Science Center (2012 - Present)

Honors & Awards

  • "Healthcare Hero", New Orleans CityBusiness Journal (2008)
  • Member (Outstanding Alumnus-Tulane University), The Paul Tulane Society (2008)
  • Member, Founder's Circle Stanford University (2009)
  • "Best Doctor", America's Best Doctors (2005-2014)
  • America's Top Surgeons, Consumer's Research Council of America (2005-2012)

Professional Education

  • Internship:Tripler Army Medical Center GME Training Verifications (1982) HI
  • Medical Education:Tulane University School of Medicine (1981) LA
  • Board Certification: Neurological Surgery, American Board of Neurological Surgery (1990)
  • Residency:Walter Reed Army Medical Center (1987) DC
  • M.D., Tulane University, Medicine (1981)
  • B.S., University of California, Irvine, Biological Sciences (1978)

Research & Scholarship

Current Research and Scholarly Interests

My interest for many years has focused on neuro-oncology (brain tumors) and utilizing both surgery and stereotactically focused radiation to treat solid tumors of the nervous system primarily utilizing the CyberKnife.

In addition, I am an expert in complex and minimally invasive spine surgery.

More recently, my interests revolve around understanding the neural, social and mental bases of compassion and altruism using a multi-disciplinary approach.


2017-18 Courses


All Publications

  • A randomized controlled trial of compassion cultivation training: Effects on mindfulness, affect, and emotion regulation MOTIVATION AND EMOTION Jazaieri, H., McGonigal, K., Jinpa, T., Doty, J. R., Gross, J. J., Goldin, P. R. 2014; 38 (1): 23-35
  • Enhancing Compassion: A Randomized Controlled Trial of a Compassion Cultivation Training Program JOURNAL OF HAPPINESS STUDIES Jazaieri, H., Jinpa, G. T., McGonigal, K., Rosenberg, E. L., Finkelstein, J., Simon-Thomas, E., Cullen, M., Doty, J. R., Gross, J. J., Goldin, P. R. 2013; 14 (4): 1113-1126
  • Social Connection and Compassion: Important Predictors of Health and Well-Being SOCIAL RESEARCH Seppala, E., Rossomando, T., Doty, J. R. 2013; 80 (2): 411-430
  • Intramedullary spinal cord metastasis from prostate carcinoma: a case report. Journal of medical case reports Lieberson, R. E., Veeravagu, A., Eckermann, J. M., Doty, J. R., Jiang, B., Andrews, R., Chang, S. D. 2012; 6 (1): 139-?


    Although vertebral and epidural metastases are common, intradural metastases and intramedullary spinal cord metastases are rare. The indications for the treatment of intramedullary spinal cord metastases remain controversial. We present the first biopsy-proven case of an intramedullary spinal cord metastasis from adenocarcinoma of the prostate.Our patient was a 68-year-old right-handed Caucasian man with a Gleason grade 4 + 3 prostate adenocarcinoma who had previously undergone a prostatectomy, androgen blockade and transurethral debulking. He presented with new-onset saddle anesthesia and fecal incontinence. Magnetic resonance imaging demonstrated a spindle-shaped intramedullary lesion of the conus medullaris. Our patient underwent decompression and an excisional biopsy; the lesion's pathology was consistent with metastatic adenocarcinoma of the prostate. Postoperatively, our patient received CyberKnife® radiosurgery to the resection cavity at a marginal dose of 27Gy to the 85% isodose line. At three months follow-up, our patient remains neurologically stable with no new deficits or lesions.We review the literature and discuss the indications for surgery and radiosurgery for intramedullary spinal cord metastases. We also report the novel use of stereotactic radiosurgery to sterilize the resection cavity following an excisional biopsy of the metastasis.

    View details for DOI 10.1186/1752-1947-6-139

    View details for PubMedID 22657386

  • Treatment of cavernous sinus tumors with linear accelerator radiosurgery SKULL BASE SURGERY Chang, S. D., Doty, J. R., Martin, D. P., Hancock, S. L., Adler, J. R. 1999; 9 (3): 195-199


    Since 1989, 79 patients with benign or malignant cavernous sinus tumors, have been treated at Stanford University with linear accelerator (linac) radiosurgery. Radiosurgery has been used as (1) a planned second-stage procedure for residual tumor following surgery, (2) primary treatment for patients whose medical conditions preclude surgery, (3) palliation of malignant lesions, and (4) definitive treatment for small, well-localized, poorly accessible tumors. Mean patient age was 52 years (range, 18 to 88); there were 28 males and 51 females. Sixty-one patients had benign tumors; 18 had malignant tumors. Mean tumor volume was 6.8 cm(3) (range 0.5 to 22.5 cm(3)) covered with an average of 2.3 isocenter (range, 1 to 5). Radiation dose averaged 17.1 Gy. Mean follow-up was 46 months. Tumor control or shrinkage, or both, varied with pathology. Radiographic tumor improvement was most pronounced in malignant lesions, with greater than 85% showing reduction in tumor size; benign tumors (meningiomas and schwannomas) had a 63% control rate and 37% shrinkage rate, with none enlarging. We concluded that stereotactic radiosurgery is a valuable tool in managing cavernous sinus tumors. There was excellent control and stabilization of benign tumors and palliation of malignant lesions.

    View details for Web of Science ID 000083016700004

    View details for PubMedID 17171089

  • Clinical experience with image-guided robotic radiosurgery (the Cyberknife) in the treatment of brain and spinal cord tumors NEUROLOGIA MEDICO-CHIRURGICA Chang, S. D., Murphy, M., Geis, P., Martin, D. P., Hancock, S. L., Doty, J. R., Adler, J. R. 1998; 38 (11): 780-783


    The Cyberknife is an image-guided "frameless" dedicated radiosurgical device. This instrument has several distinct advantages over frame-based systems, including improved patient comfort, increased treatment degrees of freedom, and the potential to target extracranial lesions. Clinical results thus far with respect to the treatment of malignant intracranial tumors has been promising. Additionally, the Cyberknife will likely revolutionize the application of radiosurgery to extracranial sites. A description of the components, treatment planning, and clinical results of the Cyberknife will be reviewed.

    View details for Web of Science ID 000077103400031

    View details for PubMedID 9919913

  • The cyberknife: A frameless robotic system for radiosurgery XIIth Meeting of the World Society for Stereotactic and Functional Neurosurgery Adler, J. R., Chang, S. D., MURPHY, M. J., Doty, J., Geis, P., Hancock, S. L. KARGER. 1997: 124–28


    The Cyberknife is a unique instrument for performing frameless stereotactic radiosurgery. Rather than using rigid immobilization, the Cyberknife relies on an image-to-image correlation algorithm for target localization. Furthermore, the system utilizes a novel, light-weight, high-energy radiation source. The authors describe the technical specifications of the Cyberknife and summarize the initial clinical experience.

    View details for Web of Science ID 000074800300019

    View details for PubMedID 9711744